Recent approaches in the development of measles vaccines

  • O. Leroy


Different approaches are followed in order to develop measles vaccines which will induce a protective cellbound and humoral immunity in the face of maternal antibodies. The use of massive doses of different strains of live attenuated measles vaccines at 6 months of age have reached deadlock and the improvement of the currently used vaccines is of limited interest. The recent advances in genetic and molecular techniques pave the way for the development of recombinant and synthetic vaccines, which is closely linked to the understand ing of the molecular and structural determinant of the protective immune response. The synthetic vaccines are still at an experimental level, and it is possible to design immunogenic peptides, containing both T and B cell recognition sites. The major limitation of the synthetic vaccine approach is the unresolved question on the mechanism of the protective immunity related to the structure of the peptides -length, construction, way of presentation -and their recognition by the largest possible number of individuals. The developfrnent of adjuvants is complementary to synthetic vaccines. Different adjuvants are developed in order to enhance the immunogenicity of sub-unit vaccines. Liposomes and the immunostimulating complex (ISCOM) are the most promising for measles sub-unit vaccines. Many efforts are devoted to the development of recombinant measles vaccines. The construction of recombinant measles vaccines is based on the insertion of the genes coding for the fusion and haemagglutinin proteins of the measles virus envelope in poxvirus vaccines used as vectors. Vaccinia, fowlpox and canarypox viruses are the most commonly used vectors. There are strong experimental demonstrations of the expression of the recombinant antigens at sufficient levels, inducing humoral and protective immunity.


Measle Virus Recombinant Vaccine Canine Distemper Virus Maternal Antibody Measle Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    (1992) Measles control in the 1990s: plan of action for global measles control. WHO/EPI/ GEN/92.3Google Scholar
  2. 2.
    Miller C (1987) Live measles vaccine: a 21-year follow-up. BMJ 295: 22–24PubMedCrossRefGoogle Scholar
  3. 3.
    Markowitz LE ,Preblud S, Fine PEM, Orenstein WA (1990) Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J 9: 101–110PubMedCrossRefGoogle Scholar
  4. 4.
    Black FL (1989) Measles active and passive immunity in a worldwide perspective. Prog Med Virol 36: 1–33PubMedGoogle Scholar
  5. 5.
    Krober MS, Stracener CE, Bass JW (1991) Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds. JAMA 265: 2095–6PubMedCrossRefGoogle Scholar
  6. 6.
    Edmonson MB, Davis JP (1992) Measles vaccination (MV) during the respiratory virus season as a risk factor for vaccine failure, 32nd Interscience conference on Antimicrobial Agents and Chemotherapy (ICAAC) Anaheim, California, USAGoogle Scholar
  7. 7.
    Halsey NA, Boulos R, Mode F, Andréj, Bowman L, Yaeger RG, Toureau S, RohdeJ, Boulos C (1985) Response to measles vaccine in Haitian infants 6 to 12 months old. New Engl J Med 313: 544–549PubMedCrossRefGoogle Scholar
  8. 8.
    Ndikuyeze A, Munoz A, Stewart J, Modlin J, Heymann D, Herrmann KL, Polk BF (1988) Immunogenicity and safety of measles vaccine in ill African children. Int J Epidemiol 17: 448–455PubMedCrossRefGoogle Scholar
  9. 9.
    Harris MF (1977) The safety of measles vaccine in severe illness. S Afr Med J: 38Google Scholar
  10. 10.
    Enders JF, Peebles TC (1954) Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med 86: 277–286PubMedGoogle Scholar
  11. 11.
    Sabin AB, Arechiga AF, Fernandez de Castro J, Albrecht P, Sever JL, Shekarchi I (1984) Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. JAMA 251: 2363–2371PubMedCrossRefGoogle Scholar
  12. 12.
    Mirchamsy H, Bahrami S, Shafyi A, Kamali M, Razavi J, Nazari, Razavi J, Ahouri P, Fatemi S, M Amin-Salehi M (1977) A comparative field trial of five measles vaccines produced in human diploîd cell, MRC5. J Biol Stand 5: 1–18PubMedCrossRefGoogle Scholar
  13. 13.
    Sabin A, Albrecht P, Takeda AK, Ribeiro EM, Veronesi R (1985) High effectiveness of aerosolized chick embryo fibroblast measles vaccine in seven-month-old and older infants. J Infect Dis 152: 1231–1237PubMedCrossRefGoogle Scholar
  14. 14.
    Khanum S, Garelick H, Uddin N, Mann G, Tomkins A (1987) Comparison of Edmonston-Zagreb and Schwarz strains of measles vaccine given by aerosol or sub cutaneous injection. Lancet: 150–153Google Scholar
  15. 15.
    Zourbas J (1971) Essais cliniques et immunologiques comparatifs de 4 lots de vaccin antirougeoleux Schwarz de titres differents. La Femme et l’Enfant 4: 5–17Google Scholar
  16. 16.
    Makino S (1983) Development and characteristics of live AIK-C measles virus vaccine: a brief report. Rev Infect Dis 5: 504–505PubMedCrossRefGoogle Scholar
  17. 17.
    Whittle H, Eccles M, Jupp L, Hanlon L, Mann G, O’Neill K, Hanlon P, Marsh V (1988) Effects of dose and strain of vaccine on success of measles vaccination of infants aged 4’5 months. Lancet: 963–966Google Scholar
  18. 18.
    Markowitz LE, Sepulveda J, Diaz-Ortega JL, Valdespino JL, Albrecht P, Zell ER, Stewart J, Zarate ML, Bernier RH (1990) Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. New Engl J Med 322: 580–587PubMedCrossRefGoogle Scholar
  19. 19.
    Tidjani O, Guérin N, Lecam N, Grunitsky B, Levy-Bruhl D, Xueref C, Tatagan K (1989) Serological effects of Edmonston-Zagreb, Schwarz and AIK-C measles vaccine strains given at ages 4’5 or 8’10 months. Lancet: 1357–60Google Scholar
  20. 20.
    Kiepiela P, Coovadia HM, Loening WE, Coward P, Botha G, Hugo J, Becker PJ (1991) Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants. Bull WHO 69: 221–7PubMedGoogle Scholar
  21. 21.
    Wassilak S, Orenstein W, Strickland P, Butler C, Bart K (1985) Continuing measles transmission in students despite a school-based outbreak control program. Am J Epidemiol 122:208–217PubMedGoogle Scholar
  22. 22.
    Adu FD, Akinwolere OAO, Tomori O, Uche LN (1992) Low seroconversion rates to measles vaccine among children in Nigeria. Bull WHO 70:457–460PubMedGoogle Scholar
  23. 23.
    Albrecht P ,Ennis FA ,Saltzman EJ, Krugmann S (1977) Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr 91:715–718PubMedCrossRefGoogle Scholar
  24. 24.
    Sabin A (1983) Immunization against measles by aerosol. Rev Infect Dis 5: 514–523PubMedCrossRefGoogle Scholar
  25. 25.
    Aaby P, Hansen JL, Tharup J, Sodemann M, Knudsen K, Jensen TG, Kristiansen H, Poulsen A, Jakobsen M, Da Silva MC ,Whittle H (1988) Trial of high-dose Edmonston Zagreb measles vaccine in Guinea-Bissau: protective efficacy. Lancet: 809–814Google Scholar
  26. 26.
    Job JS ,Halsey NA ,Boulos R ,Holt E ,Farrell D ,Albrecht P ,Brutus JR ,Adrien M ,Andrej, Chan E, Kissinger P, Boulos C, Cité Soleil/JHU Project Team (1991) Successful immunization of infants at 6 months of age with high dose Edmonston-Zagreb measles vaccine. Pediatr Infect Dis J 10: 303–11PubMedCrossRefGoogle Scholar
  27. 27.
    Whittle H, O’Neill K, Marsh V, Hanlon P, Hanlon L, Jupp E, Aaby P (1988) Trial of high-dose Edmonston-Zagreb measles vaccine in the Gambia: antibody response and side-effects. Lancet: 811–814Google Scholar
  28. 28.
    Gareme M, Leroy O, Beau JP, Sene I (1992) High-titer measles vaccines: protection evaluation. ForthcomingGoogle Scholar
  29. Garenne M, Leroy O ,Beau JP ,Sene I Efficacy of measles vaccines when controlling for exposure. ForthcomingGoogle Scholar
  30. 30.
    Garenne M ,Leroy O ,Beau JP ,Sene I ,Whittle H ,Sow AR (1991) Efficacy, safety and immunogenicity of two high-titer measles vaccines: a study in Niakhar, Senegal. Final report. ORSTOM, DakarGoogle Scholar
  31. 31.
    Garenne M, Leroy O, Samb B, Beau JP ,Whittle H ,Sene I ,Sow AR (1991) Survival after measles vaccination with high titer vaccines given at five months of age. In WHO consultation on mortality rates following administration of measles vaccine before nine months ,Geneva. Working paper #2Google Scholar
  32. 32.
    Garenne M ,Fontaine O (1986) Assessing probable causes of deaths using a standardized questionnaire. In IUSSP (ed.) A study in rural Senegal. Seminar on morbidity and mortality. Sienna: 123–142Google Scholar
  33. 33.
    Garenne M ,Leroy O ,Beau J ,Sene I (1991) Child mortality after high-titre measles vaccines in Senegal -the complete data set -reply. Lancet 338: 1518–1519CrossRefGoogle Scholar
  34. 34.
    Garenne M ,Leroy O ,Beau JP ,Sene I (1991) Child mortality after high-titre measles vaccines -prospective study in Senegal. Lancet 338: 903–907PubMedCrossRefGoogle Scholar
  35. 35.
    Weiss R (1992) Measles battle loses potent weapon. Science 258: 546–547PubMedCrossRefGoogle Scholar
  36. 36.
    (1992) EPI. Safety of high titer measles vaccines. Week Epi Rec 67: 357–361Google Scholar
  37. 37.
    Minor P (1992) La voie périlleuse vers un vaccin rougeoleux amélioré. CVI Forum 2:8–10PubMedGoogle Scholar
  38. 38.
    Mestecky J ,Eldridge JH (1991) Targeting and controlled release of antigens for the effective induction of secretory antibody responses. Curr Opin Immunol 3: 492–495PubMedCrossRefGoogle Scholar
  39. 39.
    Barrett T (1987) The molecular biology of the morbillivirus (measles) group. Biochem SocSymp 53: 25–37Google Scholar
  40. 40.
    Norrby E (1975) Occurence of antibodies against envelope components after im munization with formalin inactivated and live measles vaccine. J Biol Stand 3: 375–380PubMedCrossRefGoogle Scholar
  41. 41.
    Norrby E ,Enders-Ruckle G (1975) Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus. J Infect Dis 132: 262–269PubMedCrossRefGoogle Scholar
  42. 42.
    Norrby E ,Lagercrantz R (1976) Measles vaccination. VII. The occurence of antibodies against virus envelope components after immunization with inactivated vaccine. Effects of revaccination with live measles vaccine. Acta Paed Scand 65: 171–176CrossRefGoogle Scholar
  43. 43.
    Norrby E (1985) Measles vaccination ,today and tomorrow. Ann Inst Pasteur/Virol 136 E: 561–570CrossRefGoogle Scholar
  44. 44.
    Sato TA ,Kohama T ,Sugiura A (1989) Protective role of human antibody to the fusion protein of measles virus. Microbiol Immunol 33: 601–607PubMedGoogle Scholar
  45. 45.
    Mäkelä MJ ,Marusyk RG ,Norrby E ,Tyrrell DLJ, Salmi AA (1989) Antibodies to measles virus surface polypeptides in an immunized student population before and after booster vaccination. Vaccine 7: 541–545PubMedCrossRefGoogle Scholar
  46. 46.
    Bellanti JA ,Sanga RL ,Klutinis B ,Brandt B ,Artenstein MS (1969) Antibody responses in serum and nasal secretions of children immunized with inactivated and attenuated measles virus vaccines. N Eng J Med 280: 628–633CrossRefGoogle Scholar
  47. 47.
    Heffner RR ,Schluederberg AE (1967) Specificity of the primary and secondary antibody responses to myxoviruses. J Immunol 98: 668–672PubMedGoogle Scholar
  48. 48.
    Pedersen IR ,Mordhorst CH ,Ewald T ,Von Magnus H (1986) Long-term antibody response after measles vaccination in an isolated Arctic society in Greenland. Vaccine 4: 173–178PubMedCrossRefGoogle Scholar
  49. 49.
    Graves M, Griffin DE, Johnson RT, Hirsch RL, Lindo de Soriano I, Roedenbeck S, Vaisberg A (1984) Development of antibody to measles virus polypeptides during complicated and uncomplicated measles virus infections. J Virol 49: 409–412PubMedGoogle Scholar
  50. 50.
    Bech V (1959) Studies on the development of complement fixing antibodies in measles patients. Observations during a measles epidemic in Greenland. J Immunol 83: 267–275PubMedGoogle Scholar
  51. 51.
    Brunell PA (1990) EPI, Measles control in the 1990s: Measles serology. WHO/EPI/ GEN/90.4Google Scholar
  52. 52.
    Liebert U ,ter Meulen V (1987) Virus aspects of measles virus-induced encephalomyeletis in Lewis and Bn rats. J Gen Virol 68: 1715–1722PubMedCrossRefGoogle Scholar
  53. 53.
    Brinckmann UG ,Bankamp B ,Reich A, ter Meulen V, Liebert UG (1991) Efficacy of individual measles virus structural proteins in the protection of rats from measles encephalitis. J Gen Virol 72: 2491–2500PubMedCrossRefGoogle Scholar
  54. 54.
    Varsanyi TM, Utter G, Norrby E (1984) Purification ,morphology and antigenic characterization of measles virus envelope components. J Gen Virol 65: 355PubMedCrossRefGoogle Scholar
  55. 55.
    Nadel S ,McGann K ,Hodinka RL ,Rutstein R, Chatten J (1991) Measles giant cell pneumonia in a child with human immunodeficiency virus infection. Pediatr Infect DisJ 10: 542–4CrossRefGoogle Scholar
  56. 56.
    Shelhamer JH, Toews GB ,Masur H ,Suffredini AF ,Pizzo PA ,Walsh TJ ,Hender son DK (1992) Respiratory Disease in the Immunosuppressed Patient. Ann Int Med 117:415–431PubMedGoogle Scholar
  57. 57.
    Burnet FM (1968) Measles as an index of immunological function. Lancet 2:610–613PubMedCrossRefGoogle Scholar
  58. 58.
    van Binnendijk RS ,Poelen MCM ,de Vries P ,Uytedehaag FGCM ,Osterhaus ADME (1990) A role for CD8 + class I MHC-restricted CTLs in recovery from measles: implications for the development of inactivated measles vaccines. In Modern approaches to new vaccines including the prevention of AIDS. Cold Spring Harbor Laboratory Press: 299–303Google Scholar
  59. 59.
    Von Pirquet C (1908) Das verhalten der kutanen tuberkulin reaktion wärhend der masern. Deutsche Med Wochenschr 34: 1297–1300CrossRefGoogle Scholar
  60. 60.
    Joffe MI ,Rabson AR (1981) Defective helper factor (LMF) production in patients with acute measles infection. Clin Immunol Immunopathol 20: 215–223PubMedCrossRefGoogle Scholar
  61. 61.
    Ward BJ ,Johnson RT ,Vaisberg A ,Jauregui E ,Griffin DE (1990) Spontaneous Proliferation of Peripheral Mononuclear Cells in Natural Measles Virus Infection: Identification of Dividing Cells and Correlation with Mitogen Responsiveness. Clin Immunol Immunopathol 55: 315–326PubMedCrossRefGoogle Scholar
  62. 62.
    Hirsch RL ,Griffin DE ,Johnson RT ,Cooper SG ,Lindo de Soriano I ,Roedenbeck S ,Vaisberg A (1984) Cellular immune response during uncomplicated measles virus infections of man. Clin Immunol Immunophathol 31: 1–12CrossRefGoogle Scholar
  63. 63.
    Griffin DE ,Ward BJ ,Jauregui E ,Johnson RT ,Vaisberg A (1989) Immune activation in measles. New Engl J Med ,320: 1667–1672PubMedCrossRefGoogle Scholar
  64. 64.
    Griffin DE (1991) Immunologie abnormalities accompanying acute and chronic viral infections. Rev Infect Dis 13 (Suppl 1): 129–133CrossRefGoogle Scholar
  65. 65.
    Norrby E ,Utter G ,Orvell C ,Appel M (1986) Protection against canine distemper virus in dogs after immunization with isolated fusion protein. J Virol 58: 536PubMedGoogle Scholar
  66. 66.
    Drillien R ,Spehner D ,Kirn A ,Giraudon P ,Buckland R ,Wild F ,Lecocq JP (1988) Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein. Proc Natl Acad Sci USA 85: 1252–1256PubMedCrossRefGoogle Scholar
  67. 67.
    Malvoisin E, Wild F (1990) Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge ,J Virol 64: 5160–5162PubMedGoogle Scholar
  68. 68.
    Bankamp B ,Brinckmann UG ,Reich A ,Niewiesk S ,ter Meulen V ,Liebert UG (1991) Measles virus nucleocapsid protein protects rats from encephalitis. J Virol 65: 1695–1700PubMedGoogle Scholar
  69. 69.
    Steward MW ,Stanley SM ,Dimarchi R ,Mulcahy G ,Doel TR (1991) High-affinity antibody induced by immunization with a synthetic peptide is associated with protection of cattle against foot-and-mouth disease. Immunology 72: 99–103PubMedGoogle Scholar
  70. 70.
    Milich DR (1989) Synthetic T and B cell recognition sites: implications for vaccine development. Adv Immunol 45: 195–264PubMedCrossRefGoogle Scholar
  71. 71.
    Alkhatib G ,Briedis DJ (1986) The predicted primary structure of the measles virus hemagglutinin. Virology 150: 479–484PubMedCrossRefGoogle Scholar
  72. 72.
    Richardson C ,Hull D ,Greer P ,Hasel P ,Berkovich A ,England D ,Bellini W ,Rima B ,Lazzarini R (1986) The nucleotide sequence of the mRNA encoding the fusion protein of the measles virus (Edmonston strain): a comparison of fusion proteins from several paramyxoviruses. Virology 155: 508–523PubMedCrossRefGoogle Scholar
  73. 73.
    Partidos CD ,Steward MW (1990) Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans. J Gen Virol 71: 2099–2105PubMedCrossRefGoogle Scholar
  74. 74.
    Partidos CD ,Stanley CM, Steward MW (1991) Immune responses in mice following immunization with chimeric synthetic peptides representing B and T cell epitopes of measles virus proteins. J Gen Virol 72: 1293–1299PubMedCrossRefGoogle Scholar
  75. 75.
    Partidos CD ,Steward MW (1992) The effects of a flanking sequence on the immune response to a B-cell and a T-cell epitope from the fusion protein of measles virus. J Gen Virol 73: 1987–1994PubMedCrossRefGoogle Scholar
  76. 76.
    Arnon R ,Horwitz RJ (1992) Synthetic peptides as vaccines. Curr Opin Immunol 4: 449–453PubMedCrossRefGoogle Scholar
  77. 77.
    Mougin B ,Bakouche O ,Gerlier D (1988) Humoral immune response elicited in rats by measles viral membrane antigens presented in liposomes and ISCOMs. Vaccine 6: 445–449PubMedCrossRefGoogle Scholar
  78. 78.
    Garnier F ,Forquet F ,Bertolino P ,Gerlier D (1991) Enhancement of in vivo and in vitro T cell response against measles virus haemagglutinin after its incorporation into liposomes: effect of the phospholipid composition. Vaccine 9: 340–5PubMedCrossRefGoogle Scholar
  79. 79.
    Bomford R ,Stapleton M ,Winsor S ,Beesley JE ,Jessup EA ,Price KR ,Fenwick GR (1992) Adjuvanticity and ISCOM formation by structurally diverse saponins. Vaccine 10:572–577PubMedCrossRefGoogle Scholar
  80. 80.
    Morein B ,Sundquist B ,Höglund S ,Dalsgaard K ,Osterhaus A (1984) Iscom ,a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308: 457–460PubMedCrossRefGoogle Scholar
  81. 81.
    Speijers GJA ,Danse LHJC ,Beuvery EC ,Strik JJTWA ,Vos JG (1988) Local reactions of the saponin quil A and a quil A containing Iscom measles vaccine after intramuscular injection of rats: a comparison with the effect of DPT-Polio vaccine. Fundamental and applied Toxicology 10: 425–430PubMedCrossRefGoogle Scholar
  82. 82.
    De Vries P ,Van Binnendijk RS ,Van der Marel P ,Van Wezel AL ,Voorma HO ,Sundquist B, Uytdehaag FGCM, Osterhaus ADME (1988) Measles virus fusion protein presented in an immune-stimulating complex (Iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies ,virus-specific T cells and protection in mice. J Gen Virol 69: 549PubMedCrossRefGoogle Scholar
  83. 83.
    Pedersen IR ,Bog-Hansen TC ,Dalsgaard K ,Heegaard PMH (1992) Iscom immunization with synthetic peptides representing measles virus hemagglutinin. Virus Research 24: 145–159PubMedCrossRefGoogle Scholar
  84. 84.
    Osterhaus ADME ,De Vries P (1992) Vaccination against acute respiratory virus infections and measles in man. Immunobiology 184: 180–192PubMedCrossRefGoogle Scholar
  85. 85.
    Esposito JJ, Murphy FA (1989) Infectious recombinant vectored virus vaccines. In Advances in veterinary science and comparative medicine. Academic Press Inc: 195–247Google Scholar
  86. 86.
    Wild TF, Malvoisin E, Buckland R (1991) Measles virus: both the haemagglutinin and fusion glycoproteins are requied for fusion ,J Gen Virol 72: 439–442PubMedCrossRefGoogle Scholar
  87. 87.
    Spehner D ,Kirn A ,Drillien R (1991) Assembly of nucleocapsidlike structures in animal cells infected with a vaccinia virus recombinant encoding the measles virus nucleoprotein, J Virol 65: 6296–300PubMedGoogle Scholar
  88. 88.
    Wild TF, Giraudon P, Spehner D, Drillien R, Lecocq JP (1990) Fowlpox virus recombi nant encoding the measles virus fusion protein: protection of mice against fatal measles encephalitis. Vaccine 8: 441–2PubMedCrossRefGoogle Scholar
  89. 89.
    Tartaglia J, Pincus S, Paoletti E (1990) Poxvirus-based vectors as vaccine candidates. Crit Rev Immunol 10: 13–30PubMedGoogle Scholar
  90. 90.
    Taylor J, Weinberg R, Tartaglia J, Richardson C ,Alkhatib G ,Briedis D, Appel M, Norton E, Paoletti E (1992) Nonreplicating viral vectors as potential vaccinesrecombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 187: 321–328PubMedCrossRefGoogle Scholar
  91. 91.
    Taylor J, Pincus S, Tartaglia ,Richardson C ,Alkhatib G ,Briedis D ,Appel M ,Norton E ,Paoletti E (1991) Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge. J Virol 65: 4263–4274PubMedGoogle Scholar
  92. 92.
    Vialard J ,Lalumière M ,Vernet T ,Briedis D ,Alkhatib G ,Henning D ,Levin D ,Richardson C (1990) Synthesis of the membrane fusion and hemagglutinin proteins of measles virus ,using a novel baculoviurs vector containing the beta-galactosidase gene. J Virol 64: 37–50PubMedGoogle Scholar
  93. 93.
    Takehara K ,Hashimoto H ,Ri T ,Mori T ,Yoshimura M (1992) Characterization of baculovirus-expressed hemagglutinin and fusion glycoproteins of the attenuated measles virus strain AIK-C ,Virus Research 26: 167–175PubMedCrossRefGoogle Scholar
  94. 94.
    Pastoret PP, Brochier B (1990) Le virus de la vaccine et ses proches parents. Ann Méd Vét 134:207–220Google Scholar
  95. 95.
    Tartaglia J ,Perkus ME ,Taylor J ,Norton EK ,Audonnet J-C ,Cox WI ,Davis SW ,van der Hoeven J ,Meignier B ,Rivière M ,Languet B ,Paoletti E (1992) NYVAC: a highly attenuated strain of vaccinia virus. Virology 188: 217–232PubMedCrossRefGoogle Scholar
  96. 96.
    Smith GL ,Moss B (1984) Vaccinia virus expression vectors: construction ,properties and applications. Biotechniques: 306–312Google Scholar
  97. 97.
    Wild TF ,Bernard A ,Spehner D ,Drillien R (1992) Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice. J Gen Virol 73: 359–367PubMedCrossRefGoogle Scholar
  98. 98.
    Brochier B ,Kieny MP ,Costy F ,Coppens P ,Bauduin B ,Lecocq JP ,Languet B ,Chappuis G ,Desmettre P ,Afiademanyo K ,Libois R ,Pastoret P-P (1991) Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 354: 520–522PubMedCrossRefGoogle Scholar
  99. 99.
    Moss B (1990) Poxviridae and their replication. In BN Fields ,DM Knipe et al (eds.) ,Virology ,Raven Press Ltd ,New York: 2097–2111Google Scholar
  100. 100.
    Taylor J ,Paoletti E (1988) Fowlpox as a vector in non-species. Vaccine 6: 466–468PubMedCrossRefGoogle Scholar
  101. 101.
    Taylor J ,Weinberg R Languet B ,Desmettre P ,Paoletti E (1988) Recombinant fowlpox virus inducing protective immunity in non-aviarí species. Vaccine 6: 497–503PubMedCrossRefGoogle Scholar
  102. 102.
    Taylor J ,Trimarchi C ,Weinberg R ,Languet B ,Rivière M ,Desmettre P ,Paoletti E (1991) Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 9: 190–193PubMedCrossRefGoogle Scholar
  103. 103.
    Cadoz M ,Strady A ,Meignier B ,Taylor J ,Tartaglia J ,Paoletti E ,Plotkin S (1992) Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 339: 1429–1449PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1993

Authors and Affiliations

  • O. Leroy
    • 1
  1. 1.Pasteur Mérieux Sérums et VaccinsMarnes-La-CoquetteFrance

Personalised recommendations